

GVIRF Webinar

Vaccine Adjuvants for Global Health

September 13th, 2023 09:00-12:30 EDT

Virtual webinar, Register [here](#)

Introduction

The biennial Global Vaccine and Immunization Research Forum ([GVIRF](#)) and the associated [GVIRF Webinar](#) series are global convenings that bring together the Vaccine and Immunization Research community, from basic immunology to implementation research, and from low to high income countries to address research challenges, innovations, and opportunities to facilitate vaccine research and development and maximize the benefit of immunization. Both the GVIRF and the Webinars are co-organized by the US National Institute of Allergy & Infectious Diseases (NIAID), the Bill & Melinda Gates Foundation (BMGF), and the World Health Organization (WHO), with the objective to facilitate progress towards the Strategic Goals of Immunization Agenda 2030 ([IA2030](#)).

This webinar is to discuss issues related to global demand for vaccine adjuvants and the associated research and development, as well as facilitating global access to novel adjuvants and formulation technologies for vaccine developers.

AGENDA

08:30 EDT Audio and video check-in for speakers and panelists only

09:00 EDT Welcome and introduction

Annie Mo, Senior Program Officer, Division of Microbiology and Infectious Diseases (DMID), NIAID, US

09:02 EDT Session I: Global demand for vaccine adjuvants

Co-Chairs: Christopher Fox, SVP, Formulations, Access to Advanced Health Institute (AAHI), US;
Annie Mo, Senior Program Officer, DMID, NIAID, US

Needs for a global market

Nicolas Collin, Co-founder and CEO, Vaccine Formulation Institute (VFI), Switzerland

Adjuvants for pandemic preparedness

Daniel Fullen, Senior manager, Coalition for Epidemic Preparedness Innovation (CEPI), UK

Empowering public health: strengthening capacity for global supply, accessibility and affordability for adjuvants and formulations

Dexiang Chen, CEO, Maxvax, China

Panel discussion: speakers and additional panelists, 25 mins

Additional panelists:

Krishna Mohan, Executive Director, Bharat Biotech, India

Paulo Lee Ho, Manager, Product Development, Instituto Butantan, Brazil

10:05 EDT Break

10:10 EDT Session II: Selection of adjuvant and formulation for vaccine R&D: rational or empirical?

Co-Chairs: Cesar Boggiano, Chief, Preclinical Research and Development, Division of AIDS, NIAID, US;
Anastazia Older Aguilar, Program Officer, BMGF, US

Molecular mechanism of adjuvants and how to best present to immune system

Kevin Saunders, Associated Director, Duke Human Vaccine Institute, US

Formulation impact on vaccine performance

Shannon Miller, Director, Project Management, Inimmune Corp., US

Adjuvant performance in target populations - RV460 HIV vaccine trial in Kenya

Josphat Kosgei, Principal Investigator, US Army Medical Research Unit, Kenya

Regulatory considerations for adjuvants for new and improved vaccines

Marion Gruber, Vice President, Public Health and Regulatory Science, International AIDS Vaccine Initiative

Panel discussion: all speakers, 15 mins

11:15 EDT Break**11:20 EDT Session III: Access to adjuvants_ “speed dating” for vaccine developers**

(Flash talks to showcase new and novel adjuvants/formulation technologies with clinical experiences. Contact information for global access will be provided)

Chair: Wolfgang Leitner, Section Chief, Innate Immunity, Division of Allergy, Immunology, and Transplantation, NIAID, US

Novel synthetic Th1 and Th17 inducing adjuvants, David Burkhart, Associate Director, the Center for Translational Medicine, University of Montana, US

Advax-CpG adjuvant, Nikolai Petrovsky, Founder and Research Director, Vaxine Pty Ltd., Australia

Alhydroxiqum-II, Sunil A. David, CEO, ViroVax LLC, US

The CAF adjuvant platform: a versatile adjuvant/delivery platform for proteins & peptides, Gabriel Pedersen, Head of Section, Vaccine Adjuvant Research, Statens Serum Institute (SSI), Denmark

ALF adjuvant, Mangala Rao, Chief, Laboratory of Adjuvant & Antigen Research, Walter Reed Army Institute of Research (WRAIR), US

Intranasal vaccine adjuvant for prevention of respiratory and sexually-transmitted infections, Chad Costley, CEO, BlueWillow Biologics Inc, US

dmLT/LTA1 adjuvant, Elizabeth Norton, Associate Professor, Tulane University, US

BECC family of adjuvants, Robert K. Ernst, Professor and Chair, Department of Microbial Pathogenesis, University of Maryland, US

VFI adjuvant portfolio, Celine Lemoine, Head of VFI laboratory in Epalinges, VFI, Switzerland

AAHI adjuvant portfolio, Christopher Fox, SVP, Formulations, AAHI, US

12:20 EDT Closing remarks and forward looking**Global health perspectives on new adjuvants and formulation technologies**

Martin Friede, Coordinator, Initiative for Vaccine Research, WHO, Switzerland

12:30 EDT Adjourn